

1 **Title: Cryo-EM structure of an elusive pre-transport intermediate of the multidrug**
2 **ABC transporter BmrCD reveals modes of asymmetric drug binding**

3

4 **Authors:** Tarjani M. Thaker^{1*}, Smriti Mishra^{2*}, Wenchang Zhou³, Jose D. Faraldo-
5 Gomez³, Hassane S. Mchaourab^{2,#}, Thomas M. Tomasiak^{1,#}

6 **Affiliations:**

7 ¹Department of Chemistry and Biochemistry, University of Arizona, 1041 E Lowell St.
8 Tucson, AZ 85719, USA

9 ²Department of Molecular Physiology and Biophysics, Vanderbilt University, 2215
10 Garland Avenue, Nashville, TN 37232, USA

11 ³Theoretical Molecular Biophysics Laboratory, National Heart, Lung, and Blood Institute,
12 National Institutes of Health, 50 South Drive, Bethesda, MD 20892, USA

13 *These authors contributed equally to this work

14 #Correspondence to: tomasiak@arizona.edu; hassane.mchaourab@vanderbilt.edu

15 **ABSTRACT:** Vectorial substrate efflux by ATP binding cassette (ABC) transporters,
16 which play a major role in multidrug resistance, entails the ATP-powered
17 interconversion of the transporter between stable intermediates. Despite recent
18 progress in structure elucidation of ABC transporters, a number of such intermediates
19 have yet to be visualized and mechanistically interpreted. Here, we combine single
20 particle cryo-EM, Double Electron Electron Resonance (DEER) spectroscopy with
21 Molecular Dynamics simulations to profile and mechanistically frame the conformation
22 of a hitherto unobserved intermediate in the context of BmrCD, a heterodimeric
23 multidrug ABC exporter from *Bacillus subtilis*. In our cryo-EM structure, BmrCD adopts
24 an inward-facing architecture bound to both ATP and the substrate Hoechst-33342 and
25 is capped by an extracellular domain which undergoes ATP-dependent conformational
26 changes. A striking feature of the structure is a symmetric arrangement of the
27 nucleotide-binding domain (NBD) in the presence of ATP whereas binding of Hoechst at
28 two distinct sites in an acidic pocket stabilizes an asymmetric arrangement of the
29 transmembrane domain architecture (TMD). Mutation of residues coordinating Hoechst
30 in the structure abrogates the cooperative stimulation of ATP hydrolysis. In conjunction
31 with previous studies, our findings suggest a mechanistic role for symmetry mismatch
32 between NBDs and TMDs in the conformational cycle of ABC transporters. Moreover,
33 the resolved structures of bimodally-bound drugs are of notable importance for future
34 rational design and optimization of molecules for targeted transport inhibition of ABC
35 transporters.

36 **ONE SENTENCE SUMMARY:** Cryo-EM and EPR analysis reveal cooperative substrate
37 binding in BmrCD in an architecture primed for transport.

38 INTRODUCTION

39 ATP binding cassette (ABC) transporters harness the energy of ATP hydrolysis
40 to traffic molecules across lipid membranes. Ubiquitous in all kingdoms of life, ABC
41 exporters efflux a spectrum of substrates, most notably cytotoxic drugs¹⁻³. Although the
42 molecular architecture of ABC transporters invariably has two nucleotide binding
43 domains (NBD) with two ATP binding sites (also referred to as the nucleotide binding
44 site (NBS)) and two transmembrane domains (TMDs), a subfamily has evolved a
45 catalytically impaired NBD. Typically assembled as heterodimers, ABC exporters of this
46 subfamily are distinguished by an asymmetric duty cycle of the motor domain where
47 ATP hydrolysis is primarily carried out by the active ATP binding site¹, also known as
48 the consensus NBS. The mechanistic implications of the asymmetric ATP turnover
49 continue to be an active area of investigation.

50 Owing to the widespread application of single particle cryo-EM, the structural
51 biology of ABC exporters has witnessed rapid advances in the last few years yielding
52 snapshots of transporters in distinct conformational states. Most notably, a complement
53 of such states was resolved for a bacterial ABC heterodimer, TmrAB⁴. These included
54 inward-facing (IF) conformations, occluded and outward-facing (OF) conformations, and
55 for the first time a post-hydrolysis low energy state where asymmetric binding of ATP
56 and ADP was resolved. Current models of ATP-driven transport posit that ABC
57 transporters rest in an inward-facing open conformation with NBDs slightly separated for
58 high affinity substrate and nucleotide binding, though recent studies report nucleotide
59 binding in this architecture is constitutive at least in exporters¹. The ATP-substrate-
60 transporter complex is then in a state favorable for transport once both NBDs are

61 aligned to form an intact ATP hydrolysis pocket. Conserved loops (Walker A, Walker B)
62 present in most ATPases, and motifs (Q-loop) that are specific only to ABC transporters
63 coordinate the positioning of a catalytic water by a highly conserved glutamate residue
64 in the Walker B motif resulting in ATP hydrolysis and the subsequent reset of the
65 transport cycle.

66 Despite the success of the TmrAB investigation in linking intermediates of ATP
67 hydrolysis to distinct conformations, significant mechanistic gaps remain. One critical
68 gap pertains to the sequence of events that occur prior to transition to OF conformations
69 after substrate and ATP binding. Except ABC homodimers, structures of ATP-bound
70 ABC exporters almost invariably have been obtained in a catalytically-impaired
71 background where both NBD catalytic glutamates were replaced with Glutamines⁴⁻⁶.
72 Moreover, these structures as well as those of ATP-bound TmrAB, capture outward
73 facing or occluded conformations⁵⁻¹⁰. This has led to a generalized conclusion that ATP
74 binding stabilizes the OF conformation despite evidence that the stability of such a
75 conformation may be transporter dependent¹¹. Furthermore, prior to this transition, a
76 loaded IF intermediate bound to substrate and ATP must be postulated. Such an
77 intermediate could be transient for TmrAB, explaining its absence in the cryo-EM maps.

78 A second, heterodimer-specific mechanistic gap, pertains to the nature of drug
79 binding. Efforts to sensitize drug-resistant cells to various small molecules and
80 chemotherapeutics by inhibiting efflux pumps such as heterodimeric ABC transporters
81 has not yet proven successful^{12,13}. In the absence of a detailed understanding of
82 determinants of transporter/drug interactions, progress on this front remains stalled.
83 Some insights have emerged from recent structures of P-glycoprotein (Pgp) visualizing

84 substrates¹⁴ and inhibitors¹⁵ cradled in the vestibule between the TMDs with
85 stoichiometries of one and two per transporter, respectively. In contrast, the peptide
86 substrate was poorly resolved in TmrAB structures precluding an analysis of the role of
87 asymmetry in heterodimer substrate recognition, although substrate binding shifted the
88 equilibrium towards a more open IF conformation⁴.

89 To address these two central mechanistic gaps, we integrated cryo-EM with
90 Double Electron Electron Resonance (DEER) spectroscopy, Molecular Dynamics (MD)
91 simulations, and biochemical analysis to determine, validate and mechanistically
92 contextualize the structure of a pre-transport, ATP-bound, Hoechst-loaded intermediate
93 of the ABC heterodimer BmrCD from *Bacillus subtilis*. BmrCD was selected on the basis
94 of previous DEER analyses demonstrating that the ATP-bound IF intermediate is
95 relatively stable^{11,16}. We further enriched this intermediate in a catalytically impaired
96 mutant background where putative catalytic residues in both NBDs have been replaced
97 with glutamine. Hoechst is transported by BmrCD in inside-out-vesicles and stimulates
98 ATP turnover of the purified transporter in detergent micelles and nanodiscs^{11,17}. The
99 transporter structure adopts an IF conformation characterized by symmetric, yet
100 disengaged NBDs, but structurally asymmetric transmembrane domains. DEER
101 distributions in the mutant background reveal that the cryo-EM conformation is a minor
102 population in the ensemble. Notably, the cryo-EM maps reveal two antiparallel Hoechst
103 molecules bound in the IF cavity, making contacts primarily with the BmrC protomer and
104 seemingly reflecting the internal symmetry of the protein structure. Microsecond MD
105 trajectories are consistent with this interpretation and reveal the network of polar and
106 aromatic interactions that stabilizes both substrate molecules concurrently. The

107 predicted binding mode and stoichiometry of Hoechst is further interrogated by
108 functional analysis and determination of Hill coefficients in wild-type (WT) BmrCD. We
109 found that Hoechst-mediated stimulation of ATP hydrolysis is cooperative, and mutation
110 of residues in contact with the Hoechst molecules blunts stimulation of ATP hydrolysis.
111 In conjunction with DEER analysis, our structure integrates a number of recent results
112 and fills in a key gap in the mechanistic understanding of ATP-coupled conformational
113 dynamics of ABC exporters.

114

115 **RESULTS**

116 **The structure of BmrCD in the substrate and ATP-bound state adopts an inward-** 117 **open architecture**

118 The structure of BmrCD was determined using single particle cryo-electron
119 microscopy (cryo-EM) (**Fig. 1A-C; Table 1; Supp. Fig. 1**) of a cysteine-less (C-less)
120 BmrCD bearing glutamine substitution of D500 in BmrC and E592 in BmrD (referred to
121 hereafter as BmrCD-QQ). The transporter was purified into LMNG micelles which were
122 subsequently exchanged for digitonin micelles to facilitate orientation distribution on
123 cryo-EM grids (see methods). BmrCD-QQ for cryo-EM structure determination was pre-
124 saturated with excess ATP and the model substrate Hoechst-33342 (Hoechst) to
125 stabilize the ligand-bound intermediate. From an initial dataset consisting of nearly 4.3
126 million particles, we determined a structure to 3.5Å resolution from a subset of 157,021
127 particles in which the topology of the entire architecture of BmrCD is revealed in
128 sufficient detail to define the topology of a TMD insertion in BmrD, between TM2 and
129 TM3 which we define as the BmrCD extracellular domain (ECD) (**Fig. 1A-D; Supp. Fig.**

130 **2).** Notably, this domain forms a cap over the extracellular gate of the heterodimer
131 stabilized in an IF conformation where the extracellular side is closed. Within the TMD
132 we also observe two molecules of Hoechst in a central vestibule and a molecule of ATP
133 in each NBD (**Fig. 1B**). Comparison of the observed geometry to the series of IF
134 structures of the closely related exporter TmrAB highlights a wider IF architecture in
135 BmrCD with NBDs slightly separated (**Fig. 2A**) relative to the narrow inward-facing open
136 (PDB ID: 6raf⁴) (RMSD 5.424 Å) or the inward-facing wide conformation of TmrAB (PDB
137 ID: 6rag⁴; RMSD 3.624 Å), both of which are also stabilized by nucleotide binding in the
138 NBS (**Supp. Fig. 3, Supp. Table 2**). In comparison to other prokaryotic exporters of
139 known structure^{8-10,18-21} and related members of the ABCB^{5,14,15,22} and ABCC^{6,7}
140 families, BmrCD geometry is most similar in architecture to the heterodimeric exporter
141 TM287/288 asymmetrically bound to AMP-PNP in one NBS (PDB ID: 4q4a²¹; RMSD
142 3.135 Å) (**Supp. Fig. 4, 5**). However, the conformation of BmrCD is unique in that it is
143 both substrate and ATP-bound yet is inward-facing.

144

145 **The ATP and Hoechst-bound IF conformation has symmetric but disengaged** 146 **NBDs**

147 Because previous structures of ATP-bound catalytically impaired ABC
148 transporters have captured occluded or OF conformations^{5,6,8}, we characterized the
149 ensemble of conformations of the impaired BmrCD-QQ background, solubilized either in
150 digitonin or β -DDM micelles, using DEER distance measurements between pairs of spin
151 labels. Consistent with these previous studies, distance distributions in the TMD (spin
152 label pairs 96/188 and 55/146) report a predominantly OF conformation in the presence

153 of Hoechst and ATP although a minor IF population, which we presume is captured in
154 the cryo-EM structure, is evident in the distance distributions (**Fig. 1D**). Corresponding
155 DEER distributions in the wild-type C-less BmrCD background (WT) previously
156 published are shown for reference¹¹.

157 The structure presented here features symmetric NBDs, and NBSs (**Fig. 2A-C**),
158 consistent with DEER data (**Fig. 2D**). Distance distributions between spin labels
159 introduced in proximity to the degenerate (348/532) and consensus (440/441) ATP
160 binding sites for the QQ background are similar to those obtained in the Vanadate-
161 trapped intermediate of C-less BmrCD (**Fig. 2D**). As previously observed for the EQ
162 double mutants in P-glycoprotein (Pgp)⁵, the D500Q and E592Q mutations present in
163 BmrCD-QQ abrogate the asymmetry of the NBS observed under turnover conditions
164 (solid green traces in **Figure 2D**) in the C-less background. The distance distributions at
165 the NBS pairs predicted from the structure overlap with those experimentally observed
166 in C-less BmrCD in the presence of AMP-PNP (dashed green traces in **Figure 2D**).

167 In the structure, the geometry of ATP binding is also symmetric and adopts
168 nearly identical conformations (**Fig. 2B,C**). The unambiguous density into which ATP
169 was modeled appears in a canonical site for nucleotide binding that overlaps with ATP
170 in TmrAB⁴ and AMP-PNP in TM288/287²¹. In this orientation, the Walker A motif
171 stabilizes the β -phosphate of ATP, whereas the glutamine residue in place of the
172 catalytic base is oriented in proximity to the γ -phosphate in both protomers (**Fig. 2C**).
173 Unexpectedly, the NBDs of BmrC of BmrD do not contact each other, and nucleotide
174 binding is supported entirely by intra-domain interactions that stabilize ATP within a
175 well-defined cleft. These results support the following two conclusions: 1) The NBD

176 architecture of our structure is more consistent with inward-facing open populations of
177 BmrCD that are stabilized by non-hydrolyzable AMP-PNP and 2) this state is more
178 symmetric in the NBDs than in WT BmrCD in the presence of Hoechst and ATP.

179

180 **Architecture and ATP-dependent dynamics of the ECD domain**

181 A unique feature that distinguishes BmrCD from other biochemically
182 characterized ABC exporters, is the presence of the ECD. The Electron Potential
183 Density corresponding to this domain reveals a primarily β -stranded domain consisting
184 of two approximate subdomains of similar topology (**Fig. 1D; 3A**). The ECD is
185 positioned in an orientation that results in extensive interactions with the TMD thereby
186 occluding the extracellular TMD bundle of both BmrC and BmrD. Analysis of the
187 electrostatic distribution over the surface of the ECD and at ECD/TMD interface further
188 reveal both acidic and basic patches that extend into the TMD (**Fig. 3B,C**). An acidic
189 stretch of residues extends from the ECD to the BmrC TMD; whereas, the ECD/TMD
190 interface in BmrD is marked by a basic stretch. Somewhat surprising is the formation of
191 a solvent accessible, acidic cavity in the ECD. Binding of both Hoechst molecules in the
192 BmrCD TMD is observed in a similarly acidic vestibule (see below), suggesting
193 translocation of substrate through the TMD may proceed via interaction with and
194 rearrangement of the ECD.

195 We tested the notion of a functional role for the ECD by measuring distances
196 between a spin label on this domain (BmrD 126) relative to the two spin labels
197 monitoring the extracellular packing of BmrC (55) and BmrD (146) (**Fig. 3D**). The
198 ECD/BmrC interface site (46/126) undergoes a large amplitude distance opening in the

199 high-energy post hydrolysis state (red traces in **Figure 3**). Similarly, the 55/126 pair
200 report a large distance change as would be expected if the ECD moved in concert with
201 BmrD. On the other hand, we observed a small distance change between the BmrD
202 TMD (146) and the ECD (126) suggesting ATP-coupled rearrangement of this domain
203 within the BmrD protomer.

204

205 **The ATP and Hoechst-bound IF conformation features asymmetry of the** 206 **transmembrane domain**

207 Similar to TmrAB and TM287/288, BmrC and BmrD come together to form a
208 vestibule presumably to enable substrate binding. However, this assembly is
209 asymmetric in the TMD of BmrCD (**Supp. Table 1**). Superposition of the BmrD TMD
210 onto the BmrC TMD by rotation around the pseudosymmetric axis of the TMD dimer
211 highlights an outward shift of nearly every TM in BmrC relative to BmrD on the
212 extracellular side (**Fig. 4A**). The arrangement of the intracellular side of the TMD bundle
213 is similarly marked by a concerted outward movement of all BmrC TM helices relative to
214 BmrD. The intracellular side also exhibits the most substantial reorientations,
215 specifically of TM3, 4, and 6 in BmrC which shift away from the substrate binding cavity
216 by $\sim 4\text{\AA}$ relative to BmrD. The presence of several π -helices along the TMD bundle likely
217 accommodates the independent movement of the TMD helices on the two sides of the
218 membrane leaflet.

219 Comparison of the pseudosymmetric arrangement of the TMD in BmrCD to the
220 TmrAB TMD highlights similarities to wild-type TmrAB in the nucleotide-bound wide
221 state (PDB ID: 6rag⁴) and the EQ variant in the apo state (PDB ID: 6ran⁴) (**Supp. Table**

222 **2).** Even in these related architectures, substantial differences are observed in nearly
223 every TM of BmrD compared to TmrA, the equivalent canonical chain in TmrAB.
224 Comparison of the TMD geometry in related ABC exporters further highlights the
225 asymmetry of the BmrCD TMD halves (**Supp. Fig. 5**). The structures of both apo and
226 AMP-PNP-bound TM287/288 bear the strongest resemblance to the BmrCD TMD
227 geometry^{21,23}. Superposition of each half independently reveals nearly identical
228 bundles in BmrC and TM287, both of which contain the non-canonical NBS and is the
229 site of bound nucleotide in both structures (AMP-PNP in TM287). However, a
230 comparison between the homologous BmrD and TM288 chains reveals a smaller
231 interhelical angle between TM4/TM6 in BmrD (~50°) than in BmrC or TM287/TM288
232 (~60°). These differences could be due to interactions between the BmrD ECD and
233 TMD bundle, or to unique features induced by substrate binding in the BmrCD TMD.

234

235 **Asymmetric binding sites of two Hoechst molecules in the TMD**

236 Remarkably, density observed in the TMD vestibule accommodated the
237 assignment of not just one but two molecules of Hoechst. Calculation of a cross-
238 correlation score was used to rationalize a parallel or antiparallel arrangement of the
239 two molecules, with the latter scoring higher (0.65 (antiparallel) versus 0.60 (parallel))
240 thus supporting an antiparallel assignment reinforced by complimentary local
241 hydrophobic interactions. The Hoechst binding sites are also on each side of a
242 secondary pseudosymmetric two-fold axis relating the NBDs and are positioned
243 asymmetrically relative to the pseudosymmetric axis of the TMD, primarily adjacent to
244 BmrC (**Fig. 4B-D**). Furthermore, binding pocket-lining residues differ between the two

245 halves, i.e. they are non-equivalent from BmrC to BmrD (**Fig. 4H-I**), likely because the
246 TMD segment lining the substrate vestibule itself is asymmetric (**Fig 4A; Supp. Fig. 5**).
247 Nonetheless, BmrC residues L130, F134, and W290 form the surface of both binding
248 pockets which consist of chemically similar environment defined by aromatic residues
249 (pocket 1 – F293; pocket 2 – F83 and F134) and capped by an acidic residue (pocket 1
250 – E297; pocket 2 – D141).

251

252 **Antiparallel Hoechst molecules are stabilized by analogous interaction patterns**

253 To evaluate the interpretation of the distinct densities observed within the BmrCD
254 transmembrane domain as two antiparallel Hoechst molecules, and to pinpoint the
255 specific interactions that underpin their stabilization, we turned to all-atom molecular
256 dynamics (MD) simulations (**Fig. 4E-G**). Specifically, we calculated two independent 1-
257 μ s trajectories in which the transporter and the two Hoechst molecules are free to
258 diffuse, or reconfigure, and evaluated the resulting structure in each case. For
259 computational efficiency, we considered a protein construct that lacks the nucleotide-
260 binding domains and the ECD inserted between TM1 and TM2 of BmrD was also
261 truncated (**Fig. 4E**). In the cryo-EM structure, these domains contribute minimally to the
262 BmrC-BmrD interface, which primarily involves contacts in the transmembrane domains.
263 The simulated construct showed a high degree of similarity to the starting structure
264 throughout the calculated trajectories, with average backbone RMSD values of 1.6 ± 0.2
265 Å over the last 0.5 μ s (**Fig. 5F**). The two Hoechst molecules initially modeled also
266 remained stably bound, each forming multiple contacts with BmrC, but barely any with
267 BmrD (**Figs. 4G-I; Supp. Fig. 6**). For both molecules, the two simulations resulted in

268 similar poses and interaction patterns; this convergence is reassuring as it indicates
269 both MD trajectories sample the same energetically favorable states. The information
270 from the MD trajectories was used to optimally place the Hoechst molecules in the cryo-
271 EM density.

272 Unlike the two molecules of ATP in the BmrCD NBSs, the two molecules of
273 Hoechst are marked by different geometries (**Fig. 4C**). The MD simulations show
274 Hoechst-1 (*silver/purple*) is largely coordinated by residues from BmrC TM3, TM5 and
275 TM6 and one residue from BmrD TM1 and two residues from BmrD TM6 (**Fig. 4G,H**)
276 whereas Hoechst-2 (*green/yellow*) forms extensive contacts with residues primarily from
277 BmrC TM2, TM3, and TM6 (**Fig. 4G,I**). The binding pose for Hoechst-1 appears to be
278 defined by the interaction between the piperazine group (carrying a charge of +1) and
279 E297 (**Fig. 4G**). The two benzimidazole rings (which together also carry a charge of +1)
280 form additional π - π and cation- π interactions with the rings of F293 and W290, whereas
281 the ethoxy-benzene is engaged by a T-shaped aromatic interaction with Y257. Hoechst-
282 2, while oriented inversely relative to the membrane plane, is similarly anchored by ion-
283 pairing and cation- π interactions formed by the piperazine group, namely with D141,
284 F145 and W290, which is the only residue that contacts both ligand molecules in our
285 trajectories. The benzimidazole rings in molecule '2' form additional π - π and cation- π
286 interactions with the rings of F83 and F134, whereas the ethoxy-benzene tail appears to
287 be largely disengaged, in contrast to Hoechst-1 (**Fig. 4G**). These interactions, π - π and
288 cation- π interactions, are reinforced by their observation in the cryo-EM structure.
289 Interestingly, therefore, the pattern of interactions formed by the two molecules in this

290 antiparallel arrangement also appears to reflect the internal structural symmetry of the
291 TMDs.

292 Lastly, it is worth noting that these interaction patterns recapitulate what is
293 observed in high-resolution crystal structures of other biomolecules in complex with
294 Hoechst. In the outward-open structure of the MFS-family multi-drug transporter LmrP²⁴,
295 a Hoechst molecule is stabilized through ion-pairs between two acidic side chains and
296 the piperazine and benzimidazole groups, albeit in an orientation nearly perpendicular to
297 the plane of the transmembrane. The ligand is however only in contact with one of the
298 transmembrane domains, like in our structure of inward-facing BmrCD. Binding of
299 Hoechst to LmrR, a transcriptional repressor of the LmrCD drug ABC transporter,
300 involves aromatic stacking of tryptophan sidechains and the benzimidazole rings²⁵, while
301 dipole- π and water-mediated polar interactions explain the mode of binding to DNA²⁶.
302 Our cryo-EM and MD simulation data show that it is this interaction versatility that may
303 enable BmrCD to recognize two Hoechst molecules simultaneously.

304 Moreover, the arrangement and asymmetry in geometry of the two Hoechst
305 molecules in the cryo-EM structure and MD analysis (**Fig. 4C,G**) are not without
306 precedent and are reminiscent of the two molecules of the inhibitor zosuquidar bound to
307 human Pgp¹⁵ (ABCB1) where one zosuquidar molecule is extended while the other
308 molecule is in a slightly bent conformation (**Supp. Fig. 5**). Binding of these inhibitors
309 occurs at a site closer to the extracellular side, which potentially supports the occluded
310 architecture observed in Pgp. The positioning of Hoechst in BmrCD-QQ is most similar
311 to LPS bound to MsbA and overlaps with the inner core of the polysaccharide portion of

312 the molecule (**Supp. Fig. 5**)¹⁹, parallel with the presumed inner leaflet of the
313 transmembrane region.

314

315 **Cooperative Hoechst stimulation of ATP turnover is blunted by mutation of** 316 **coordination residues**

317 Because our structure reveals the presence of two bound Hoechst molecules, we
318 reasoned that mutual stabilization would result in cooperative binding of the drug. To
319 test this notion, we determined the k_{cat} of BmrCD ATP hydrolysis as a function of
320 increasing Hoechst concentrations (**Fig. 5A**). We observed a sigmoidal dependence of
321 k_{cat} with a Hill coefficient of approximately 1.8 (**Fig. 5B**). Not only does this data confirm
322 cooperativity, but it also mechanistically validates the binding of two Hoechst molecules
323 by demonstrating direct coupling to ATP hydrolysis in the NBDs.

324 Conversely, mutations of residues that coordinate the substrate molecules in the
325 structure reduce stimulation of ATP turnover (**Fig. 5C**). We targeted both acidic and
326 hydrophobic residues in the cavity identified by MD and observed in our structure.
327 Alanine substitution effects were variable but overall consistent with the residues
328 implicated in the structure. Notably, W290A which coordinates both Hoechst molecules
329 has a substantial effect on ATP stimulation. Similarly, D141 in proximity to Hoechst-2
330 abrogates the Hoechst dependence, although its basal rate is higher than for WT
331 BmrCD. This presumably reflects a rearrangement of the BmrC molecules that disrupt
332 coupling of the TMD to the NBD.

333

334 **DISCUSSION**

335 The accelerated pace of structure determination of ABC exporters set the stage
336 for an almost unprecedented structure-mechanism understanding. Yet intermediates
337 predicted to be populated in the transport cycle continue to be conspicuously absent
338 from the structural record. In addition, except for TmrAB⁴ and bacterial homodimers^{9,10},
339 the structure space has been dominated by transporters with impaired ATP-hydrolysis.
340 In the presence of ATP, these models are outward-facing with no evidence of bound
341 substrates. Based on spectroscopic^{11,27} and biochemical data²⁸, the underlying
342 mutations conspire to reshape the energy landscape further confounding the
343 mechanistic interpretation of the structural catalog.

344 The collection of TmrAB cryo-EM structures is thus far the most complete record
345 of stable intermediates on the energy landscape of an ABC exporter⁴. However, under
346 turnover conditions of excess ATP, two predicted intermediates were missing. One is
347 the outward-facing conformation which purportedly release the substrate, the absence
348 of which was attributed to its presumed transient nature. The structure of the outward-
349 facing conformation was visualized in the catalytically impaired mutant bound to ATP as
350 well as in the vanadate-trapped WT. The second, is a loaded pre-transport intermediate
351 poised for transition to the high energy outward-facing conformation. Because previous
352 structures of catalytically-impaired ABC exporters such as Pgp⁵ and Mrp1⁶ were in the
353 outward-facing conformations, a substrate- and ATP-loaded IF intermediate was not
354 accounted for.

355 Here, we report the structure of this elusive substrate- and ATP-bound,
356 intermediate. Cryo-EM reveals an IF architecture bound with two molecules of the

357 model substrate Hoechst-33342 in the TMD, and two molecules of ATP in the NBDs of
358 a catalytically impaired variant of BmrCD. Each molecule of Hoechst binds in a similarly
359 located but nonequivalent pocket on the C or D chain and our ATPase data support
360 their role in cooperative allosteric modulation of ATP turnover. Validated by DEER
361 measurements in the WT C-less and the mutant backgrounds, we assign this
362 conformation to the substrate- and ATP-loaded intermediate poised for transition to a
363 high energy, post hydrolysis intermediate. In the case presented here, previous DEER
364 data highlighted the stability of the ATP-bound IF intermediate in BmrCD which was one
365 of two fortuitous factors that allowed it to be represented in our cryo-EM reconstruction,
366 although outward facing states may also be present¹¹. The second factor is the
367 structural order of this intermediate which was conducive to its cryo-EM reconstruction.

368 Our BmrCD structure unlocks details of the nature of pseudosymmetry breaking
369 in ABC transporters and stimulates hypotheses on the mechanistic roles of symmetry
370 mismatch between the NBDs and TMDs. Alignment with the recently determined cryo-
371 EM structures of TmrAB⁴ confirms that BmrCD is in a previously unobserved
372 intermediate. Distances between NBDs are most consistent with the inward-facing wide
373 state, albeit BmrCD is wider than TmrAB. Approximately 75% of BmrCD aligns with this
374 TmrAB conformation, including all of BmrC and most of the transmembrane portion of
375 BmrD. The NBD of the canonical BmrD protomer does not align, instead showing a
376 ~40° rotation around the symmetry axis of the NBD dimer.

377 The symmetry of the NBDs holds for most of the transmembrane region but is
378 broken in several locations including TM3 and TM6, especially TM6 in BmrD. TM6 is
379 noteworthy because this helix has been identified as important for substrate

380 gatekeeping in TmrAB⁴ and in *C. elegans* Pgp²⁹. In our structure, TM6 in BmrC and
381 BmrD each directly binds one of the two Hoechst molecules which are located in similar
382 pockets in BmrC and BmrD, showing a pseudo-symmetric arrangement. However, TM6
383 from BmrC breaks that symmetry and is closer to TM3 of BmrC forming a tighter
384 interface than these two helices in BmrD. Moreover, Hoechst binds in a head-to-tail
385 antiparallel arrangement that matches that of inhibitors found in Pgp. MD simulations
386 confirm this arrangement and the stabilizing interactions that largely overlap with the
387 binding mode observed in the structure. We propose a direct relationship between the
388 asymmetry of substrate binding in the cavity and the overall asymmetry of the TMDs of
389 BmrCD.

390 An emerging theme from structural and spectroscopic investigations of ABC
391 exporters posits a role for substrates and inhibitors in stabilizing symmetric or
392 asymmetric conformations. Cryo-EM structures of Pgp have highlighted different modes
393 of inhibitors and substrates binding with the former filling more of the substrate cavity
394 and inducing a more symmetric arrangement of the NBDs¹⁴. However, substrate binding
395 induces asymmetric states both in IF conformations and post-hydrolysis conformations,
396 as deduced from DEER analysis of Pgp³⁰. Building on this theme, we propose that our
397 symmetry-mismatched BmrCD structure is arrested in an “inhibited-like conformation”
398 by the substitution of the catalytic glutamate in the consensus NBS. In a WT
399 background, we propose that the asymmetry would propagate from the TMD to the NBD
400 resulting in the asymmetric hydrolysis of ATP during transport. Indeed, extensive DEER
401 investigations of BmrCD under turnover conditions concluded that ATP hydrolysis in the
402 consensus NBS is coupled to asymmetric structure of the NBDs¹¹. We predict that

403 subsequent or concurrent transition to an OF conformation accompanied by the
404 dissociation of the substrates resolves the asymmetry in the TMD.

405 In addition to outlining the structural features and the mechanistic context of an
406 intermediate presumed to be poised for transport and revealing modes of substrate
407 interactions with a multidrug transporter, our results have general implications for the
408 field. Our structure resembles a necessary intermediate between symmetric resting
409 states without substrate and asymmetric post-hydrolysis states that have released
410 substrate. In between these states, a transition must occur that “breaks” this symmetry
411 and bring NBDs into alignment for proper catalysis to take place in one of the two
412 NBDs. This transition may reflect asymmetric loading of substrate and asymmetric
413 movements in the TMDs that allosterically facilitate NBD alignment. BmrCD only has
414 one such functional site, but a similar mechanism may be relevant for most ABC
415 exporters, which have two such sites but which nevertheless might have a preferred
416 order³¹. Thus, the absence of intermediates in the structural record of a particular
417 transporter may reflect the energetic idiosyncrasies of the transporter being investigated
418 and should not be extrapolated in the context of a general mechanism. A consensus
419 mechanism for ABC heterodimers will require the convergence of structural,
420 spectroscopic and functional investigations of multiple transporters.

421

422 **MATERIALS AND METHODS**

423 **Cloning**

424 Cysteine-less (C-less) BmrCD in pET21b(+) was created as described
425 previously¹¹. Briefly, native cysteines in wild-type BmrCD were substituted with alanines

426 using QuikChange site-directed mutagenesis. The C-less BmrCD template was then
427 used to generate BmrCD-QQ where the conserved glutamate of the Walker B motif in
428 the consensus site in BmrD (E592) and aspartate of the degenerate site in BmrC
429 (D500) were substituted with glutamine (Q). Site-directed mutagenesis of the C-less
430 BmrCD was also used to generate double-cysteine pair and substrate binding mutants.
431 All substitutions were confirmed by DNA sequencing.

432

433 **Expression and purification**

434 Wild-type C-less BmrCD and all mutant plasmids were transformed into
435 *Escherichia coli* BL21(DE3) cells. A single colony was inoculated into 20 mL Luria Broth
436 (LB) for the primary culture which subsequently was used to start the main culture
437 consisting of 1L of minimal media supplemented with glycerol (0.5% v/v), thiamin (2.5
438 µg/mL), ampicillin (100 µg/mL), MgSO₄ (1 mM), and 50X MEM amino acids (1 mL).
439 Cultures were grown at 37°C with shaking to an OD₆₀₀ of 1.2, and the expression of
440 BmrCD induced by the addition of 0.7 mM isopropyl β-D-1-thiogalactopyranoside.
441 BmrCD cultures were incubated at 25°C with shaking for another 5.5 h. The cells were
442 harvested by centrifugation and stored at -80°C. The cell pellets were resuspended in
443 20 mL of lysis buffer (50 mM Tris-HCl, 5 mM MgCl₂, 1mM EDTA, pH 7.5), including 10
444 mM DTT, 10 µg/mL DNase, 0.1 mM PMSF, 1/3 of a Complete EDTA-free protease
445 inhibitor cocktail tablet (Roche) and were lysed by five passes through an Avestin C3
446 homogenizer at 15-20,000 PSI. The lysate was centrifuged at 9,000g for 10 min to
447 remove cell debris and the membranes isolated by ultracentrifugation at ~200,000g for 1
448 h.

449 Membranes of C-less BmrCD mutants assayed in 0.05% n-dodecyl- β -D-
450 maltopyranoside (β -DDM) were solubilized in resuspension buffer (50 mM Tris-HCl, 100
451 mM NaCl, 15% (v/v) glycerol, pH 8.0) including 1 mM DTT, 1.25 % w/v β -DDM with
452 constant stirring on ice for 1 h. The membranes of double mutants studied in 0.25%
453 digitonin were solubilized in resuspension buffer (50 mM Tris-HCl, 100 mM NaCl, 15%
454 (v/v) glycerol, pH 8.0) including 1 mM DTT and 1% w/v Lauryl Maltose Neopentyl Glycol
455 (LMNG). Solubilized membranes were then centrifuged at \sim 200,000xg for 1 h to
456 remove insoluble particulates. The solubilized fraction was then incubated for 2 h with
457 300 μ L of pre-equilibrated Ni-NTA resin (QIAGEN) in Ni-NTA buffer (50 mM Tris-HCl,
458 100 mM NaCl, 15% (v/v) glycerol, 0.05% β -DDM, pH 8.0) for β -DDM samples or Ni-NTA
459 buffer 2 (50 mM Tris-HCl, 100 mM NaCl, 15% (v/v) glycerol, 0.005% LMNG, pH 8.0) for
460 digitonin samples. BmrCD-bound Ni-NTA resin was loaded into a gravity column,
461 washed with five column volumes of Ni-NTA buffer containing 20 mM imidazole and
462 eluted with buffer containing 250 mM imidazole.

463

464 **Cryo-EM sample preparation**

465 C-less BmrCD harboring the D500Q (BmrC) and D592Q (BmrD) mutations
466 (BmrCD-QQ) was prepared for cryo-EM by first exchanging sample purified by size
467 exclusion chromatography in SEC Buffer 1 (50 mM Tris-HCl, 150 mM NaCl, 0.01%
468 LMNG, 20% glycerol, pH 7.4) into SEC Buffer 2 (50 mM Tris-HCl, 200 mM NaCl, 0.06%
469 digitonin (Millipore), pH 7.4). Digitonin was added to SEC Buffer 2 from a 10% (w/v)
470 stock prepared by diluting the detergent powder in 50 mM Tris-HCl, 200 mM NaCl, pH
471 7.4 and boiling at 100°C for 5 min. The solubilized stock was diluted into detergent-free

472 buffer (50 mM Tris-HCl, 200 mM NaCl, pH 7.4) and placed at 4°C for 12-15 hours to
473 allow for impurities in the digitonin to precipitate. Prior to SEC purification, SEC Buffer 2
474 was filtered through a 0.45 µm filter to remove precipitant from solution. Next,
475 approximately 2.5 mg of SEC-purified BmrCD-QQ was buffer exchanged by two rounds
476 of 10-fold dilution with filtered SEC Buffer 2 and concentration in an Amicon Ultra-100
477 kDa centrifugal filters (Millipore) prior to SEC purification over a Superose 6 Increase
478 column (Cytiva) equilibrated in SEC Buffer 2 at 4°C (**Supp. Fig. 1**). Fractions were
479 pooled and concentrated to a final concentration of 3.1 mg/mL measured by BCA Assay
480 (Pierce). For substrate trapping, protein was diluted to a final concentration of 22 µM
481 (~2.5 mg/mL) in 50 mM Tris-HCl, 200 mM NaCl, 0.2% digitonin, pH 7.4 and incubated
482 with 75 µM Hoecsht-33342 (Thermo Fisher) on ice for 30 min prior to the addition of 8
483 mM ATP/MgCl₂. To initiate substrate trapping, the sample was heated for 1 min at 37°C
484 following the addition of ATP/MgCl₂, then briefly placed on ice prior to immediately
485 applying to freshly glow-discharged grids for cryo-preservation.

486

487 **Cryo-EM data acquisition and processing**

488 Cryo-EM data were collected on a Quantifoil 1.2/1.3 200-mesh spacing copper
489 grid (Electron Microscopy Sciences) loaded with 5 µL of BmrCD-QQ saturated with
490 Hoecsht-33342/ATP/MgCl₂ (BmrCD-QQ^{H/ATP}) and incubated for 10 s prior to blotting on
491 Whatman 1 paper for 4 s and plunge-frozen in liquid ethane using a GP2 plunge freezer
492 (Leica) equilibrated to 10°C and 85% humidity. In total, 6,919 were recorded by beam-
493 image shift on a 300 kV Titan Krios microscope (Thermo Fisher) equipped with a K3
494 Summit detector (Gatan) operated in super-resolution mode (Pacific Northwest Center

495 for Cryo-EM) at a nominal magnification of 81,000X, corresponding to a pixel size of
496 0.54 Å. Dose-fractionated movies were acquired at an electron flux of $0.82 \text{ e}^{-1}/\text{Å}^2$ per
497 frame (45 frames total) corresponding to a total dose of $37.2 \text{ e}^{-1}/\text{Å}^2$. Images were
498 recorded with a target defocus range of -0.8 to 2.1 μm .

499 Data were processed in RELION 3.0³² and 3.1³³. Frame-based motion correction,
500 2X binning, and dose weighting were performed using MotionCor2 to generate an
501 image stack with pixel size of 1.059 Å. Defocus values were estimated from motion
502 corrected, dose weighted images using CTFFIND4.1³⁴. Approximately 1,500 particles
503 were manually picked from an initial subset of micrographs and subject to likelihood-
504 based 2D classification to generate templates for automated particle picking. In total,
505 4,970,928 particles were picked, extracted at a box size of 288 pixels with 4.0 Å/pixel,
506 split into 4 subsets of 1,242,732 particles, and subject to four rounds of 2D classification
507 and particle selection to eliminate bad particles resulting in a final particle set containing
508 632,978 particles extracted to the full pixel size (1.059 Å) for 3D classification. The best
509 class selected on the basis of highest resolution and visible transmembrane density
510 yielded 157,021 particles, which were then subject to iterative rounds of 3D refinement,
511 CTF refinement and higher order aberration correction, Bayesian polishing, and
512 postprocessing in RELION to yield a final map at 3.5 Å resolution as defined by local
513 resolution calculation in RELION 3.1. Masks were generated manually in Chimera³⁵
514 from RELION and CisTEM³⁶ maps. The use of SIDESPLITTER³⁷ extensions in RELION
515 3.1 were used in the reconstruction step in later rounds of refinement with a large mask
516 to counter the effects of observed over-fitting to the detergent micelle and to ensure that

517 all map density was included. Data processing details are shown in **Supplemental**
518 **Figure 1**.

519 Model building was performed in Coot³⁸ using RELION postprocessed maps with
520 blurring and sharpening as needed generated in CCPEM³⁹. A starting structure was
521 created from TmrAB (PDBID: 6rag⁴) truncated to polyalanine. Real space refinement
522 was performed using Phenix⁴⁰ against RELION postprocessed maps. Secondary
523 structure and reference model restraints were used, as was a high nonbonded energy
524 term to ensure proper geometry. The ISOLDE⁴¹ plug-in to ChimeraX⁴² was used for
525 difficult regions and to ensure correct orientation of H-bonds. Side-chain validation was
526 performed with EMRinger⁴³ in Phenix. Placement of the Hoechst molecules was
527 performed manually in Coot and then further refined with MD simulations (see below)
528 and in Phenix. Modelling of the ECD was aided by EVcouplings^{44,45}. All structure figures
529 were made using ChimeraX and PyMol⁴⁶. EM data and atomic coordinates have been
530 deposited in EMDB (EMD-23641) and the Protein Data Bank (PDB ID: 7M33).

531

532 **MD simulations**

533 All simulations were carried out with NAMD 2.12⁴⁷ using the CHARMM36 force
534 field^{48,49} periodic boundary conditions, constant temperature (298 K) and semi-isotropic
535 pressure (1 atm), and an integration time step of 2 fs. Force-field parameters for
536 Hoechst-33342 were those developed in a previous study²⁴. Long-range electrostatic
537 interactions were calculated using PME, with a real-space cut-off of 12 Å; van der
538 Waals interactions were computed with a Lennard-Jones potential cut-off at 12 Å with a
539 smooth switching function taking effect at 10 Å. For computational efficiency, the

540 considered in the simulations comprises only the transmembrane domain, i.e.
541 extracellular (BmrD, residue 50-114) and intracellular domains (BmrC, residue 317-574;
542 BmrD, residue 411-665) were truncated. Two molecules of the ligand Hoechst-33342
543 were included; the initial binding pose was produced by manual-fitting into the cryo-EM
544 density map. The protein-ligand complex was embedded in a pre-equilibrated palmitoyl-
545 oleoyl-phosphatidyl-choline bilayer, in a 100 mM NaCl buffer, using GRIFFIN⁴⁷.
546 Counterions were added to neutralize the net charge of the protein-ligand complex. The
547 resulting system contain 206 POPC lipids and are ~90 x 90 x 126 Å in size, totaling
548 ~106,000 atoms. The molecular system was equilibrated following a staged protocol
549 comprising a series of restrained simulations. The protocol consists of both positional
550 and conformational restraints, gradually weakened over 100 ns, and individually applied
551 to protein sidechains and backbone as well as the Hoechst molecules. Subsequently,
552 two trajectories of 1 μs each were calculated, with no restraints.

553

554 **Spin-labeling of BmrCD**

555 For EPR spectroscopy, double-Cysteine mutants generated on the C-less
556 background of BmrCD were eluted following Ni-NTA purification and labeled with 20-
557 fold molar excess of 1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl methanethiosulfonate
558 (Enzo Life Sciences) at room temperature in the dark over a 4 h period, after which
559 protein samples were placed at 4 °C overnight (~15 h). The labeled protein samples in
560 β-DDM and LMNG were then separated from free label by size-exclusion
561 chromatography on a Superdex 200 Increase column (Cytiva) in buffer containing 50
562 mM Tris-HCl, 150 mM NaCl, 10% (v/v) glycerol, pH 7.4 containing 0.05% β-DDM (β-

563 DDM samples) or 0.01% LMNG (digitonin samples). The samples in 0.01% LMNG
564 containing buffer were then exchanged into digitonin buffer (50 mM Tris-HCl, 200 mM
565 NaCl, 0.06% w/v digitonin, pH 7.4). The collected fractions of spin-labeled BmrCD
566 mutants were concentrated using an Amicon Ultra-100 kDa centrifugal filters (Millipore),
567 and the final concentration determined by absorbance at 280 nm (Mean extinction
568 coefficient = $68077.5 \text{ M}^{-1} \text{ cm}^{-1}$).

569

570 **DEER sample preparation and DEER spectroscopy**

571 Spin-labeled BmrCD mutants were concentrated to 70-100 μM using Amicon
572 Ultra-100 kDa centrifugal filters (Millipore) and incubated with nucleotides or Hoechst-
573 33342. The final concentrations of ATP, AMP-PNP, vanadate, MgCl^{2+} , and digitonin
574 were 10 mM, 10 mM, 5 mM, 10 mM, and 0.25% respectively. Samples for DEER
575 analysis were cryoprotected with 24% (v/v) glycerol. Post-hydrolysis (ADP-Vi) and
576 turnover (H-ATP- MgCl^{2+}) samples prepared in digitonin buffer were incubated at 37°C
577 for 15 min and 1 min, respectively. β -DDM-solubilized protein samples were trapped in
578 the post-hydrolysis state and with AMP-PNP by incubating at 30°C for 30 min. Turnover
579 samples in β -DDM buffer conditions were incubated at 30 °C for 5min. Post-hydrolysis
580 (ADP-Vi), turnover (H-ATP- MgCl^{2+}) and AMP-PNP reactions were stopped by flash
581 freezing in a liquid nitrogen bath.

582 DEER spectroscopy was performed on an Elexsys E580 EPR spectrometer
583 operating at Q-band frequency (33.9 GHz) equipped with a 40W Amp-Q amplifier
584 (Bruker) with the dead-time free four-pulse sequence at 83 K^{50,51}. The pulse lengths
585 were 10 ns (p/2) and 20 ns (p) for the probe pulses and 40 ns for the pump pulse. The

586 frequency separation was 73 MHz. Raw DEER decays were analyzed as described
587 previously¹¹. Briefly, primary DEER decays were analyzed using home-written software
588 operating in the Matlab environment. The software carries out global analysis of the
589 DEER decays obtained under different conditions for the same spin-labeled position.
590 The distance distribution is assumed to consist of a sum of Gaussians, the number and
591 population of which are determined based on a statistical criterion. Distance
592 distributions on the BmrCD-QQ cryo-EM structure were predicted *in silico* using 1 ns
593 molecular-dynamics simulations with dummy spin labels with default parameters using
594 the DEER Spin-Pair Distributor at the CHARMM-GUI website^{52,53}. Experimental Data
595 related to **Figures 1E, 2D, and 3D** are reported in **Supplemental Figure 7**.

596

597 **ATPase assays**

598 The specific ATPase activities for wild-type (WT) and mutants of C-less BmrCD
599 were determined by an inorganic phosphate assay as previously described¹¹ with slight
600 modification. Briefly, BmrCD (20 µg) samples were incubated with increasing
601 concentrations of ATP at 30°C for 30 min under basal conditions (no Hoechst) or
602 presence of different concentrations of Hoechst. The reaction was stopped by adding
603 1% SDS and the color was developed using a 1:1 solution of ammonium molybdate (2%
604 in 1M HCl) and ascorbic acid (12% in 1M HCl). The absorbance of samples was
605 measured at a wavelength of 850 nm on a BioTek Synergy H4 microplate reader. The
606 amount of phosphate released was determined by comparison to a standard curve
607 generated from inorganic phosphate. The V_{max} of WT and mutant C-less BmrCD was

608 derived using the Levenberg-Marquart nonlinear least squares fitting approach in Origin
609 (OriginLab, Inc).

610 **ACKNOWLEDGEMENTS**

611 We thank Theo Humphries and other support staff at the Pacific Northwest
612 Center for Cryo-EM (PNCC) for assistance with cryo-EM data collection. We thank
613 members of the Tomasiak lab and Derek Claxton from the Mchaourab lab for critical
614 reading of this manuscript. This research was funded by the Division of Intramural
615 Research of the National Heart, Lung and Blood Institute (W.Z. and J.D.F.G), and
616 grants from the National Institute of General Medicine Sciences awarded to T.M.
617 Tomasiak (R00 GM114245) and H.S. Mchaourab (GM128087). Computational
618 resources were in part provided by the NIH HPC facility Biowulf.

619

620 **AUTHOR CONTRIBUTIONS**

621 This study was conceptualized by T.M. Tomasiak and H.S. Mchaourab.
622 Experimental design, investigation, and analysis were conducted by T.M. Thaker, S.M,
623 W.Z., and J.D.F.G., H.S. Mchaourab, and T.M. Tomasiak. The initial manuscript was
624 prepared by T.M. Tomasiak, T.M. Thaker, and H.S. Mchaourab, with further editing by
625 S.M. and J.D.F.G. Data presentation and visualization was conducted by T.M. Thaker
626 and S.M. Supervision of research and funding acquisition was carried out by T.M.
627 Tomasiak and H.S. Mchaourab.

628

629 **COMPETING INTERESTS**

630 The authors declare no competing interests.

631 **REFERENCES AND NOTES**

- 632 1. Holland, I. B. Rise and rise of the ABC transporter families. *Res. Microbiol.* **170**,
633 304–320 (2019).
- 634 2. Locher, K. P. Mechanistic diversity in ATP-binding cassette (ABC) transporters.
635 *Nature Structural and Molecular Biology* **23**, 487–493 (2016).
- 636 3. Thomas, C. *et al.* Structural and functional diversity calls for a new classification
637 of ABC transporters. *FEBS Lett.* **594**, 3767–3775 (2020).
- 638 4. Hofmann, S. *et al.* Conformation space of a heterodimeric ABC exporter under
639 turnover conditions. *Nature* **571**, 580–583 (2019).
- 640 5. Kim, Y. & Chen, J. Molecular structure of human P-glycoprotein in the ATP-
641 bound, outward-facing conformation. *Science* **359**, 915–919 (2018).
- 642 6. Johnson, Z. L. & Chen, J. ATP Binding Enables Substrate Release from Multidrug
643 Resistance Protein 1. *Cell* **172**, 81-89.e10 (2018).
- 644 7. Johnson, Z. L. & Chen, J. Structural Basis of Substrate Recognition by the
645 Multidrug Resistance Protein MRP1. *Cell* **168**, 1075-1085.e9 (2017).
- 646 8. Choudhury, H. G. *et al.* Structure of an antibacterial peptide ATP-binding cassette
647 transporter in a novel outward occluded state. *Proc. Natl. Acad. Sci. U. S. A.* **111**,
648 9145–9150 (2014).
- 649 9. Ward, A., Reyes, C. L., Yu, J., Roth, C. B. & Chang, G. Flexibility in the ABC
650 transporter MsbA: Alternating access with a twist. *Proc. Natl. Acad. Sci. U. S. A.*
651 **104**, 19005–19010 (2007).
- 652 10. Dawson, R. J. P. & Locher, K. P. Structure of a bacterial multidrug ABC
653 transporter. *Nature* **443**, 180–185 (2006).

- 654 11. Mishra, S. *et al.* Conformational dynamics of the nucleotide binding domains and
655 the power stroke of a heterodimeric ABC transporter. *Elife* **3**, e02740 (2014).
- 656 12. Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W. & Bates, S. E. The
657 controversial role of ABC transporters in clinical oncology. *Essays Biochem.* **50**,
658 209–232 (2011).
- 659 13. Seelig, A. P-Glycoprotein: One Mechanism, Many Tasks and the Consequences
660 for Pharmacotherapy of Cancers. *Frontiers in Oncology* **10**, (2020).
- 661 14. Alam, A., Kowal, J., Broude, E., Roninson, I. & Locher, K. P. Structural insight into
662 substrate and inhibitor discrimination by human P-glycoprotein. *Science* **363**,
663 753–756 (2019).
- 664 15. Nosol, K. *et al.* Cryo-EM structures reveal distinct mechanisms of inhibition of the
665 human multidrug transporter ABCB1. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 26245–
666 26253 (2020).
- 667 16. Collauto, A., Mishra, S., Litvinov, A., Mchaourab, H. S. & Goldfarb, D. Direct
668 Spectroscopic Detection of ATP Turnover Reveals Mechanistic Divergence of
669 ABC Exporters Article Direct Spectroscopic Detection of ATP Turnover Reveals
670 Mechanistic Divergence of ABC Exporters. *Structure* **25**, (2017).
- 671 17. Torres, C., Galián, C., Freiberg, C., Fantino, J.-R. & Jault, J.-M. The YheI/YheH
672 heterodimer from *Bacillus subtilis* is a multidrug ABC transporter. *Biochim.*
673 *Biophys. Acta - Biomembr.* **1788**, 615–622 (2009).
- 674 18. Mi, W. *et al.* Structural basis of MsbA-mediated lipopolysaccharide transport.
675 *Nature* **549**, 233–237 (2017).
- 676 19. Ho, H. *et al.* Structural basis for dual-mode inhibition of the ABC transporter

- 677 MsbA. *Nature* **557**, 196–201 (2018).
- 678 20. Angiulli, G. *et al.* New approach for membrane protein reconstitution into
679 peptidiscs and basis for their adaptability to different proteins. *Elife* **9**, (2020).
- 680 21. Hohl, M. *et al.* Structural basis for allosteric cross-talk between the asymmetric
681 nucleotide binding sites of a heterodimeric ABC exporter. *Proc. Natl. Acad. Sci. U.*
682 *S. A.* **111**, 11025–11030 (2014).
- 683 22. Esser, L. *et al.* Structures of the Multidrug Transporter P-glycoprotein Reveal
684 Asymmetric ATP Binding and the Mechanism of Polyspecificity. *J. Biol. Chem.*
685 **292**, 446–461 (2017).
- 686 23. Timachi, M. H. *et al.* Exploring conformational equilibria of a heterodimeric ABC
687 transporter. *Elife* **6**, (2017).
- 688 24. Debruycker, V. *et al.* An embedded lipid in the multidrug transporter LmrP
689 suggests a mechanism for polyspecificity. *Nat. Struct. Mol. Biol.* **27**, 829–835
690 (2020).
- 691 25. Madoori, P. K., Agustiandari, H., Driessen, A. J. M. & Thunnissen, A. M. W. H.
692 Structure of the transcriptional regulator LmrR and its mechanism of multidrug
693 recognition. *EMBO J.* **28**, 156–166 (2009).
- 694 26. Robinson, H. *et al.* 2'-Deoxyisoguanosine adopts more than one tautomer to form
695 base pairs with thymidine observed by high-resolution crystal structure analysis.
696 *Biochemistry* **37**, 10897–10905 (1998).
- 697 27. Verhalen, B. *et al.* Energy transduction and alternating access of the mammalian
698 ABC transporter P-glycoprotein. *Nature* **543**, 738–741 (2017).
- 699 28. Lusvarghi, S., Durell, S. R. & Ambudkar, S. V. Does the ATP-bound EQ mutant

- 700 reflect the pre- or post-ATP hydrolysis state in the catalytic cycle of human P-
701 glycoprotein (ABCB1)? *FEBS Lett.* (2021). doi:10.1002/1873-3468.14054
- 702 29. Jin, M. S., Oldham, M. L., Zhang, Q. & Chen, J. Crystal structure of the multidrug
703 transporter P-glycoprotein from *Caenorhabditis elegans*. *Nature* **490**, 566–569
704 (2012).
- 705 30. Dastvan, R., Mishra, S., Peskova, Y. B., Nakamoto, R. K. & Mchaourab, H. S.
706 Mechanism of allosteric modulation of P-glycoprotein by transport substrates and
707 inhibitors. *Science* **364**, 689–692 (2019).
- 708 31. Siarheyeva, A., Liu, R. & Sharom, F. J. Characterization of an asymmetric
709 occluded state of P-glycoprotein with two bound nucleotides: Implications for
710 catalysis. *J. Biol. Chem.* **285**, 7575–7586 (2010).
- 711 32. Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure
712 determination in RELION-3. *Elife* **7**, (2018).
- 713 33. Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations
714 and anisotropic magnification from cryo-EM data sets in RELION-3.1. *IUCrJ* **7**,
715 253–267 (2020).
- 716 34. Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from
717 electron micrographs. *J. Struct. Biol.* **192**, 216–221 (2015).
- 718 35. Pettersen, E. F. *et al.* UCSF Chimera - A visualization system for exploratory
719 research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).
- 720 36. Grant, T., Rohou, A. & Grigorieff, N. cisTEM, user-friendly software for single-
721 particle image processing. *Elife* **7**, (2018).
- 722 37. Ramlal, K., Palmer, C. M., Nakane, T. & Aylett, C. H. S. Mitigating local over-

- 723 fitting during single particle reconstruction with SIDESPLITTER. *J. Struct. Biol.*
724 **211**, (2020).
- 725 38. Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. *Acta*
726 *Crystallogr. Sect. D Biol. Crystallogr.* **60**, 2126–2132 (2004).
- 727 39. Wood, C. *et al.* Collaborative computational project for electron cryo-microscopy.
728 *Acta Crystallogr. Sect. D Biol. Crystallogr.* **71**, 123–126 (2015).
- 729 40. Liebschner, D. *et al.* Macromolecular structure determination using X-rays,
730 neutrons and electrons: Recent developments in Phenix. *Acta Crystallogr. Sect. D*
731 *Struct. Biol.* **75**, 861–877 (2019).
- 732 41. Croll, T. I. ISOLDE: A physically realistic environment for model building into low-
733 resolution electron-density maps. *Acta Crystallogr. Sect. D Struct. Biol.* **74**, 519–
734 530 (2018).
- 735 42. Pettersen, E. F. *et al.* UCSF ChimeraX: Structure visualization for researchers,
736 educators, and developers. *Protein Sci.* **30**, 70–82 (2021).
- 737 43. Barad, B. A. *et al.* EMRinger: Side chain-directed model and map validation for
738 3D cryo-electron microscopy. *Nat. Methods* **12**, 943–946 (2015).
- 739 44. Marks, D. S. *et al.* Protein 3D Structure Computed from Evolutionary Sequence
740 Variation. *PLoS One* **6**, e28766 (2011).
- 741 45. Hopf, T. A. *et al.* Three-dimensional structures of membrane proteins from
742 genomic sequencing. *Cell* **149**, 1607–1621 (2012).
- 743 46. The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.
- 744 47. Staritzbichler, R., Anselmi, C., Forrest, L. R. & Faraldo-Gómez, J. D. GRIFFIN: A
745 versatile methodology for optimization of protein-lipid interfaces for membrane

- 746 protein simulations. *J. Chem. Theory Comput.* **7**, 1167–1176 (2011).
- 747 48. Klauda, J. B. *et al.* Update of the CHARMM All-Atom Additive Force Field for
748 Lipids: Validation on Six Lipid Types. *J. Phys. Chem. B* **114**, 7830–7843 (2010).
- 749 49. Best, R. B. *et al.* Optimization of the additive CHARMM all-atom protein force field
750 targeting improved sampling of the backbone ϕ , ψ and side-chain χ_1 and χ_2
751 Dihedral Angles. *J. Chem. Theory Comput.* **8**, 3257–3273 (2012).
- 752 50. Jeschke, G. & Polyhach, Y. Distance measurements on spin-labelled
753 biomacromolecules by pulsed electron paramagnetic resonance. *Phys. Chem.*
754 *Chem. Phys.* **9**, 1895–1910 (2007).
- 755 51. Jeschke, G. DEER Distance Measurements on Proteins. *Annu. Rev. Phys. Chem.*
756 **63**, 419–446 (2012).
- 757 52. Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: A web-based graphical user
758 interface for CHARMM. *J. Comput. Chem.* **29**, 1859–1865 (2008).
- 759 53. Qi, Y. *et al.* CHARMM-GUI DEER facilitator for spin-pair distance distribution
760 calculations and preparation of restrained-ensemble molecular dynamics
761 simulations. *J. Comput. Chem.* **41**, 415–420 (2020).
- 762 54. Nöll, A. *et al.* Crystal structure and mechanistic basis of a functional homolog of
763 the antigen transporter TAP. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E438–E447
764 (2017).

765

766

TABLES

767

Table 1. Data collection and refinement statistics

| Refinement | | |
|----------------------------------|-------------------------|-------------|
| Lengths (Å) | 99.55, 150.38, 96.37 | |
| Atoms | 19430 (Hydrogens: 9679) | |
| Residues | Protein: 1237 | |
| Water | 0 | |
| Resolution (Å) | 3.54 | |
| Resolution Estimates (Å) | Masked | Unmasked |
| d FSC model (0/0.143/0.5) (Å) | 2.7/3.1/3.7 | 2.9/3.2/6.3 |
| B-factors (Å²) | | |
| Iso/Aniso (#) | 9751/0 | |
| Protein (min/max/mean) | 9.64/107.50/57.52 | |
| Bonds (RMSD) | | |
| Length (Å) (# > 4σ) | 0.007 | |
| Angles (°) (# > 4σ) | 1.016 | |
| Validation | | |
| MolProbity score | 1.37 | |
| Clash score | 0.57 | |
| Ramachandran plot (%) | | |
| Outliers | 0 | |
| Allowed | 6.33 | |
| Favored | 93.67 | |
| Rotamer outliers (%) | 2.19 | |
| Model vs. Data | | |
| CC (mask) | 0.69 | |
| CC (box) | 0.61 | |
| CC (peaks) | 0.50 | |
| CC (volume) | 0.65 | |
| EMRinger Score | 2.57 | |


768

769

FIGURES

770

Figure 1



771

772

Figure 1. Structure of BmrCD^{D500Q/E592Q} in complex with Hoechst-33342 and ATP.

773

A) Cryo-EM map and **B)** model of BmrCD^{D500Q/E592Q} (BmrCD-QQ) bound to ATP and


774

Hoechst-33342 (BmrCD-QQ^{H/ATP}) highlighting the geometry and arrangement of the

775 transmembrane domains (TMDs) and nucleotide binding domains (NBDs) relative to the
776 extracellular domain insertion (ECD) and the membrane. **C)** Representative density of
777 the 3.5Å resolution structure show in **(A)** and model corresponding to transmembrane
778 helix 3 from BmrD. **D)** Topology of the ECD observed in BmrCD-QQ^{H/ATP} relative to the
779 TMD. **E)** DEER distance measurements for spin label pairs on the intracellular and
780 extracellular regions of the TMD in the cysteine-free wild-type (WT) or the QQ mutant
781 background of BmrCD and in the presence of different substrates. The MDDS-derived
782 distance distributions calculated for the cryo-EM model in **(B)** is overlaid with the DEER
783 derived distance distributions. Peaks corresponding to the inward-facing (IF) or
784 outward-facing (OF) states are labeled as such.

785

Figure 2



786

787 **Figure 2. Symmetric geometry of ATP-bound NBSs in BmrCD-QQ^{H/ATP}.** A) Overview

788 of the nucleotide binding domains in the cryo-EM structure of BmrCD-QQ^{H/ATP}. B)

789 Electron Potential Density corresponding to ATP bound in the BmrC (left) and BmrD

790 (right) chains with symmetric geometries. C) Comparison of NBD secondary structure in

791 BmrC (left) and BmrD (right) highlighting the architecture of conserved motifs and the

792 orientations of ATP molecules relative to the position of the catalytic base (D500Q in


793 BmrC; E592Q in BmrD). In the inset, an overview of the atomic features of the ATP

794 binding pockets of each are shown with residues from conserved motifs colored the

795 same. The orientations shown are of the same view in which BmrD was superimposed
796 onto BmrC to highlight the symmetry of the ATP conformation in each. **D)** DEER
797 distance distributions for spin labeled pairs in C-less WT and the QQ mutant of BmrCD
798 consensus (440/441) and degenerate (348/532) nucleotide binding sites under varying
799 conditions. Superimposed in dashed green lines (MDDS) are the distance distributions
800 predicted by the structure.

801

Figure 3



802

803 **Figure 3. A dynamic role of the ECD in BmrCD catalysis. A)** Orientation of the ECD

804 in BmrCD-QQ^{H/ATP} relative to its TMD. **B)** Electrostatic distribution over the surface of


805 the BmrCD-QQ^{H/ATP} ECD and its interactions with **C)** BmrC (left) and BmrD (right). **D)**

806 ECD/TMD spin labeled pairs generated in C-less WT BmrCD to monitor the ATP-

807 dependent dynamics of the ECD.

808

Figure 4



809

Figure 4. Asymmetric binding of Hoechst-33342 in BmrCD-QQ^{H/ATP}. A)

811 Superposition of BmrD transmembrane helices (TM1-6) onto BmrC shown from the

812 extracellular (left) and intracellular (right) gates to highlight asymmetry in the TM


813 arrangement observed in the structure of BmrCD. Red arrows correspond to the

814 movement of each TM in BmrC relative to its position in BmrD. Black ellipse
815 corresponds to the symmetry axis around which BmrD was rotated during
816 superposition. **B)** Intracellular view of the arrangement of two molecules of Hoechst-
817 33342 (HT1 and HT2) modelled in the TMD cavity of BmrCD. **C)** Electron Potential
818 Density observed corresponding to HT1 and HT2 from a central slice and **D)** their
819 positioning inside of the binding pocket. **E)** All-atom simulation system, comprising the
820 transmembrane domain of BmrCD with two Hoechst molecules placed into the
821 proposed binding site, in a POPC lipid bilayer and 100 mM NaCl (BmrC, *blue*
822 surface/cartoons; BmrD, *orange* surface/cartoons; Hoechst, *yellow* spheres; lipid, *gray*
823 lines; water, *red* lines; sodium, *magenta* spheres; chloride, *green* spheres). **F)** Density
824 maps calculated from the MD trajectories for each Hoechst molecule are overlaid onto
825 the starting cryo-EM structure (*magenta/red* surfaces derive from one trajectory and
826 *cyan/yellow* from the other). **G)** Snapshot representative of the calculated density maps,
827 highlighting the configuration of the two Hoechst molecules and their seemingly most
828 significant sidechain contacts with BmrC. Hydrogen atoms are omitted for clarity.
829 Probability distributions for each of these interaction distances are shown in **Supp. Fig.**
830 **6**. The HT1 and HT2 specific interactions are summarized in (**H**) and (**I**), respectively
831 and mapped onto the respective chains colored the same as in (**B**) and (**C**). Residues
832 colored in red are observed interacting with both molecules in the cryo-EM structure.
833 Residues with an asterisk were mutated in this study and are shown as sticks in (**D**).
834 *Red* spheres correspond to residues identified as interacting with HT1 or HT2 in both
835 the cryo-EM structure and all-atom simulation.

836

Figure 5

837



838

839 **Figure 5. Cooperative stimulation of ATP turnover in BmrCD by Hoechst-33342. A)**

840 Hoechst-33342 concentration dependent stimulation of ATPase activity in C-less wild-

841 type BmrCD (WT). **B)** Dose-response curve for Hoechst-mediated stimulation of

842 ATPase activity highlighting cooperativity in C-less wild-type BmrCD (WT). The data is a

843 representation of two biological repeats and six technical repeats. **C)** Comparison of

844 Hoechst-stimulated ATPase activity relative to basal activity (fold stimulation) in C-less

845 wild-type (WT) or alanine mutants of BmrCD. Mutants selected are of a subset of

846 residues observed interacting with Hoechst-33342 in the BmrCD-QQ^{H/ATP} cryo-EM

847 structure (see **Figure 4**).

848 **Supplementary Materials**

849 **Supplemental Table 1. RMSD analysis of domain architecture in BmrCD**

| | RMSD (Å) |
|-------------|----------|
| TMD | 3.07 |
| <i>TM1</i> | 2.2 |
| <i>TM2</i> | 1.41 |
| <i>TM3</i> | 8.58 |
| <i>TM4</i> | 4.99 |
| <i>TM5</i> | 2.07 |
| <i>TM6</i> | 1.86 |
| | |
| ICLs | 2.36 |
| <i>ICL1</i> | 1.32 |
| <i>ICL2</i> | 1.19 |
| | |
| NBD | 2.85 |

850 TMD: transmembrane domain; ICLs: intracellular loops; NBD: nucleotide-binding
851 domain


852 **Supplemental Table 2. BmrCD vs. TmrAB RMSD Analysis**

| | | overall | TMD RMSD (Å) | | | | NBD RMSD (Å) | |
|----|-------------|---------|--------------|---------|---------|---------|--------------|---------|
| | | | A vs. D | B vs. D | A vs. C | B vs. C | A vs. D | B vs. C |
| IO | <i>5mkk</i> | 5.025 | 2.639 | 3.513 | 3.776 | 2.775 | 2.099 | 1.232 |
| | <i>6raf</i> | 5.424 | 2.285 | 3.612 | 4.247 | 3.813 | 2.232 | 1.394 |
| | <i>6rag</i> | 3.624 | 2.253 | 2.442 | 3.133 | 2.002 | 1.851 | 1.55 |
| | <i>6ran</i> | 3.404 | 2.159 | 2.293 | 2.927 | 1.882 | 2.316 | 1.467 |
| OO | <i>6rah</i> | 7.589 | 5.976 | 6.563 | 6.948 | 6.268 | 2.765 | 1.434 |
| | <i>6rai</i> | 6.731 | 4.731 | 5.297 | 5.557 | 3.097 | 2.683 | 1.592 |
| | <i>6raj</i> | 7.607 | 5.937 | 6.499 | 6.943 | 6.407 | 2.773 | 1.648 |
| | <i>6rak</i> | 6.757 | 4.799 | 5.371 | 5.696 | 3.291 | 2.687 | 1.627 |
| | <i>6ral</i> | 6.399 | 4.381 | 4.899 | 5.225 | 3.011 | 2.824 | 1.593 |
| | <i>6ram</i> | 6.059 | 4.029 | 4.271 | 4.822 | 2.887 | 2.712 | 1.373 |

853 IO: inward-facing open; OO: outward-facing open or occluded

854

Supplementary Figure 1



855

856


857

Supplementary Figure 1. Cryo-EM data processing of BmrCD-QQ in the Hoechst-33342 and ATP-bound state. A) Chromatogram and SDS-PAGE analysis of the peak

858 composition for BmrCD-QQ purified by size exclusion chromatography over a Superose
859 6 column equilibrated in 0.06% digitonin containing buffer prior to sample preparation
860 for cryo-EM data collection. **B)** Representative micrograph and 2D classification results
861 from cryo-EM data collected for BmrCD-QQ in the presence of equimolar ATP/MgCl₂
862 and excess Hoechst-33342. **C)** Flowchart of data processing in RELION 3.1³³. **D)** A
863 slice through the EM volume colored according to local resolution. **E)** FSC curves
864 calculated in RELION 3.1.

865

Supplementary Figure 2



866

867


868

869

Supplementary Figure 2. Cryo-EM map data quality. Model and corresponding density of BmrCD-QQ **A**) transmembrane helices (TM1-6), **B**) extracellular domain (ECD), and **C**) nucleotide binding domains (NBD).

870

Supplementary Figure 3




871

872 **Supplementary Figure 3. Analysis of NBD symmetry in BmrCD compared to**
873 **TmrAB.** Comparison of NBD geometry between BmrCD and different states of TmrAB
874 determined by x-ray crystallography (PDB ID: 5mkk⁵⁴) and cryo-EM⁴. The noncanonical
875 NBD in BmrC and TmrB are colored *cyan*, whereas the consensus NBDs of BmrD and
876 TmrA are colored *orange*. The orientations shown are relative to BmrCD and in which
877 TmrB was aligned to BmrC (marked with a *black* dot in the center to denote the
878 reference orientation). Structures of TmrAB are shown grouped by architectures
879 adopting inward-facing open states (IO) or outward-facing states (OO).

880

Supplementary Figure 4




881

882 **Supplementary Figure 4. Analysis of NBD symmetry in BmrCD compared to**
883 **representative ABC transporters.** Comparison of NBD geometry between BmrCD and
884 structures of related ABC transporters from prokaryotes (MsbA PDB IDs: 5tv4¹⁸, 6bpp¹⁹,
885 6uz2²⁰, 3b5y⁹, and 3b5z⁹, TM2987/288 PDB ID: 2hyd¹⁰, BmrA PDB ID: 6r81
886 (unpublished); McjD PDB ID: 4pl0⁸), the ABCB (or Pgp) family^{5,14,15,22}, and ABCC
887 family^{6,7}. The noncanonical NBDs, or the first NBD (half 1) in homomeric or single
888 polypeptide transporters, are colored *cyan*, whereas the consensus NBDs, or the
889 second NBD in homomeric or single polypeptide transporter, are colored *orange*. The
890 orientations shown are relative to BmrCD in which half 1 was aligned to BmrC (marked
891 with a black dot in the center to denote the reference orientation). Structures are shown
892 grouped by architectures adopting inward-facing open states (IO) or outward-facing
893 states (OO).

894

Supplementary Figure 5




895

896 **Supplementary Figure 5. Analysis of BmrCD TMD in comparison to closely**
897 **related ABC exporters. A)** Overview of the transmembrane domain (TMD) geometry in
898 BmrCD and related inward-facing states of related prokaryotic (PDB IDs: 6rag⁴, 6bpp¹⁹,
899 and 4q4a²¹) and occluded human ABC transporters bound with inhibitor (PDB ID:
900 7a6f¹⁵) or substrate (PDB ID: 6qex¹⁴). The extracellular domain of BmrD and both
901 nucleotide binding domains have been omitted for clarity. Sites on the extracellular and
902 intracellular gates labeled for DEER experiments in BmrCD and the homologous
903 residues in the related exporters are shown as spheres and colored the same as
904 Figures 1 of the main text, where the non-canonical nucleotide-binding site containing
905 half are colored *cyan* (BmrC in BmrCD), and the canonical NBS containing half are
906 colored *orange* (BmrD in BmrCD). **B)** The C α RMSD resulting from superposition of
907 each TMD half within each structure is mapped onto the structure of the non-canonical
908 half. The scale bar above represents the minimum, median, and maximum RMSD
909 calculated for each superposition. The geometry and RMSD distribution in each are
910 shown for the **C)** outside-facing (top) and **D)** inside-facing (bottom) regions of the TMDs
911 to highlight the variation in asymmetry in each structure. Numbers in the RMSD
912 representation correspond to the transmembrane helix number.

913

Supplementary Figure 6



914

915

Supplementary Figure 6. Examination of the Hoechst-33342 binding pose with MD

916

simulations. Data is shown for two independent MD trajectories (*black, red*) of the

917

BmrCD construct shown in Fig. 4E, with two Hoechst molecules bound. **A)**

918

Quantification of ionic and aromatic interactions between Hoechst molecule '1' and

919

residues in BmrC, in terms of probability distributions of the minimum distance between

920


the ligand and each sidechain (excluding hydrogens). The only significant contact of

921

Hoechst molecule '1' with BmrD is also indicated. **B)** Same as **A)**, for molecule '2'.

922

Supplementary Figure 7



923

924

925

926

Supplementary Figure 7. A) Cartoon representations of BmrCD subdomains

highlighting the position of spin-labeled cysteine pairs generated in the nucleotide

binding domain (NBD), transmembrane domain (TMD), and the extracellular domain

927 (ECD). DEER decay signals and distance distributions for spin-labeled Cysteine pairs
928 generated in the **B**) NBD, **C**) TMD, and **D**) ECD for the QQ-mutant of C-less BmrCD.
929 The shaded regions represent confidence bands. **E**) ATP turnover rates (V_{max}) in C-
930 less BmrCD (BmrCD) and spin-labeled cysteine-pairs.